You are here:

Estradiol & levonorgestrel patches (FemSeven Conti®)

Advice

Recommended for use within NHS Scotland.

RECOMMENDATION

FemSeven Conti® offers an alternative continuous combined hormone replacement therapy (HRT) for the treatment of oestrogen deficiency symptoms in postmenopausal women more than one year after menopause. It is formulated as a transdermal patch and is the first continuous combined HRT patch to allow once weekly application. It is not licensed for prophylaxis of osteoporosis.

HRT patches are in general more expensive than oral preparations.

Drug Details

Drug Name: Estradiol & levonorgestrel patches (FemSeven Conti®)
SMC Drug ID: 28/02
Manufacturer: Merck Serono Ltd
Indication: Hormone replacement therapy for oestrogen deficiency symptoms in post-menopausal women more than one year after menopause.
BNF Category:
Sub Category: 6.4 Sex Hormones
Submission Type: Full submission
Status: Accepted
Date Advice Published: 10 January 2003

Back